CLARITY PHARMACEUTICALS LIMITED (CU6)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CU6 - CLARITY PHARMACEUTICALS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$7.37

11 Sep
2024

-0.130

OPEN

$7.60

-1.73%

HIGH

$7.60

697,098

LOW

$7.31

TARGET
$10.00 35.7% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
CU6: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 9.5 - 14.7 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-15.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx46.9
Net Operating Cash Flow xxxxxxxxxxxxxxx-43.2 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-39.29 %
Return on Invested Capital xxxxxxxxxxxxxxx-39.29 %
Return on Assets xxxxxxxxxxxxxxx-36.56 %
Return on Equity xxxxxxxxxxxxxxx-39.29 %
Return on Total Capital xxxxxxxxxxxxxxx-52.26 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-43.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx137 M
Price To Book Value xxxxxxxxxxxxxxx11.55

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx56 M
Research & Development xxxxxxxxxxxxxxx46 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

19/02/2024

-1

No Rating

-

Management at Clarity Pharmaceuticals will now push for a Phase 3 trial -for detection of prostrate cancer lesions in patients with biochemical recurrence (BCR)- after initial positive findings from the Phase1/2 diagnostic trial, explains Morgans.

The trial results showed the treatment was broadly safe, observes the analyst, and show potential to detect earlier stage disease.

Clarity is within Morgans 'Keeping Stock' research designation, whereby no forecasts, target or rating are assigned.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

08/08/2024

1

Overweight

$8.48

15.06%

Wilsons raises its price target for Clarity Pharmaceuticals to $8.48 from $4.50 to recognise an expansion of the portfolio into alpha-emitting isotopes (225Ac-bisPSMA) to complement the lead beta asset 67Cu-SARbisPSMA.

The higher target also stems from the rapid rate at which the prostate-specific membrane antigen (PSMA) PET/CT market in prostate cancer in the US is expanding, explains the broker.

The Overweight rating is maintained. No changes are made to the broker's earnings forecasts.

FORECAST
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -13.40 cents.
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -17.10 cents.
Access Extra Coverage Research History >

CU6 STOCK CHART

FNArena News on CU6

1
Australian Broker Call *Extra* Edition – Aug 08, 2024

Aug 08 2024 - Daily Market Reports
2
Rudi’s View: Gold, Healthcare, Staples & Copper

Jul 11 2024 - Rudi's View
3
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
4
Rudi’s View: Met Coal, Banks, GenAi & Buying-The-Dip

Jul 04 2024 - Rudi's View
5
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps

Latest Medical Equipment & Devices News

1
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
2
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
3
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
4
ResMed Silences The Doubters

Apr 29 2024 - Australia
5
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
6
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
7
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
8
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
9
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps
10
ResMed Recovery Turns Into Hollywood Script

Jan 31 2024 - Australia